1. Pal T., Permuth-Wey J., Betts J.A. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases//Cancer. - 2005. - V. 104. - N 12. - P. 2807 - 16.

2. Rooth C. Ovarian cancer: risk factors, treatment and management//Br J Nurs. - 2013. - V. 22. - N 17. - P. S23 - 30.

3. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2019. 250 с.

4. Ebell M.H., Culp M.B., Radke T.J. A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer//Am J Prev Med. - 2016. - V. 50. - N 3. - P. 384 - 94.

5. NCCN guidelines panel. Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer). Version 1.2016//published online: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian. - 2016. - P. OV1.

6. Stiekema A., Boldingh Q.J., Korse C.M. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin//Gynecol Oncol. - 2015. - V. 136. - N 3. - P. 562 - 6.

7. Santotoribio J.D., Garcia-de la Torre A., C. et al. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors//Eur J Gynaecol Oncol. - 2016. - V. 37. - N 1. - P. 26 - 9.

8. Colombo N., Peiretti M., Garbi A. et al. Non-Epithelial Ovarian Cancer: ESMO Clinical Practice Guidelines//Ann Oncol. - 2012. - V. 23 (Suppl 7). - P. vii20 - vii26.

9. Ledermann J.A., Raja F.A., Fotopoulou C. et al. Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines//Ann Oncol. - 2013. - V. 24 (Suppl 6). - P. vi24 - vi32.

10. Sankaranarayanan R. Screening for cancer in low- and middle-income countries//Ann Glob Health. - 2014. - V. 80. - N 5. - P. 412 - 7.

11. Yadav B.S., Sharma S.C., Robin T.P. Synchronous primary carcinoma of breast and ovary versus ovarian metastases.//Semin Oncol. - 2015. - V. 42. - N 2. - P. e13 - 24.

12. Stuart G., Kitchener H., Bacon M. et al. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Int J Gynecol Cancer 2011; 21: 750Y755.

13. Trimbos J.B., Parmar M., Vergote I. et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15; 95 (2): 105 - 12.

14. Vergote I., Trope C.G., Amant F. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer//N Engl J Med. - 2010. - V. 363. - P. 943 - 53.

15. Young R.C., Walton L.A., Ellenberg S.S. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer//N Engl J Med. - 1990. - V. 322. - P. 1021 - 7.

16. Young R.C., Brady M.F., Nieberg R.M. et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - A Gynecologic Oncology Group study//J Clin Oncol 2003. - V 21. - N 23. P. 4350 - 5.

17. Bolis G., Colombo N., Pecorelli S. et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica//Ann Oncol. - 1995. - V. 6, N 9. - P. 887 - 93.

18. Oza A.M., Cook A.D., Pfisterer J. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial//The Lancet Oncology. 2015. - V. 16, N 8. - P. 928 - 936.

19. Gershenson D., Bodurka D., Coleman R. et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum//J Clin Oncol. - 2017. In print.

20. Rustin G.J., Vergote I., Eisenhauer E. et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)//Int J Gynecol Cancer. - 2011. - V 21, N 2. - P. 419 - 23.

21. Harter P., du Bois A., Hahmann M. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial//Ann Surg Oncol. - 2006. - V. 13, N 12. - P. 1702 - 10.

22. Harter P., Sehouli J., Reuss A. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO//Int J Gynecol Cancer. - 2011. - V. 21, N 2. - P. 289 - 95.

23. Rustin G.J., van der Burg M.E., Griffin C.L. et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial//Lancet. - 2010. - V. 376, N 9747. - P. 1155 - 63.

24. Markman M., Rothman R., Hakes T. et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389 - 393, 1991.

25. Gore M., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these components. Gynecol Oncol 36: 207 - 211, 1990.

26. Mahner S., Meier W., du Bois A. et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer. 2015 Feb; 51 (3): 352 - 8.

27. The ICON and AGO Collaborators Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial//Lancet. - 2003. - V. 361. - P. 2099 - 106.

28. Hoskins P.J., Le N. Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer//Gynecologic Oncology. 2005. - V. 97. - P. 862 - 869.

29. Aghajanian C., Goff B., Nycum L.R. et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer//Gynecol Oncol. - 2015. - V. 139, N 1. - P. 10 - 6.

30. Pujade-Lauraine E., Hilpert F. Weber B. et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial//J Clin Oncol. - 2014. - V. 32. - P. 4014 - 4025.

31. Okamoto A., Sugiyama T., Hamano T. et al. Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study//J Clin Oncol. - 2014. - V. 32, N 5s (suppl; abstr 5507).

32. Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Sato S., Naniwa J., Uegaki K., Nonaka M., Terakawa N. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy//Cancer Sci. - 2009. - V. 100, N 3. - P. 546 - 51.

33. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul; 15 (8): 852 - 61.

34. Swenerton K.D., Santos J.L., Gilks C.B. et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers//Annals of Oncology. - 2011. - V. 22. - P. 341 - 347.

35. Holt K.A., Mogensen O., Jensen P.T., Hansen D.G. Goal setting in cancer rehabilitation and relation to quality of life among women with gynaecological cancer//Acta Oncol. - 2015. - V. 54, N 10. - P. 1814 - 23.

36. Harter P., Sehouli J., Lorusso D. et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms//N Engl J Med. - 2019. - V. 380. - P. 822 - 832.

37. Schofield C., Newton R.U., D.A. et al. A Physiological Profile of Ovarian Cancer Survivors to Inform Tailored Exercise Interventions and the Development of Exercise Oncology Guidelines//Int J Gynecol Cancer. - 2017. - V. 27, N 7. - P. 1560 - 1567.

38. Whicker M., Black J., Altwerger G. et al. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer//Am J Obstet Gynecol. - 2017. - V. 217, N 4. - P. 395 - 403.

39. Клинические рекомендации по лечению хронического болевого синдрома у взрослых пациентов при оказании паллиативной медицинской помощи. 2016. http://cr.rosminzdrav.ru.

40. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92: 715 - 727.

41. Nilsson H., Angeras U., Bock D., M., Onerup A., Fagevik Olsen M., Gellerstedt M., Haglind E., Angenete E. Is preoperative physical activity related to post-surgery recovery? BMJ Open. 2016 Jan 14; 6 (1): e007997. doi: 10.1136/bmjopen-2015-007997.

42. Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg. 2017 Mar; 39: 156 - 162. doi: 10.1016/j.ijsu.2017.01.111. Epub 2017 Feb 2.

43. Silver J.K., Baima J. Cancer prehabilitation: An opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013; 92: 715 - 27.

44. Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol. 2015 Dec; 22 (13): 4117 - 23. doi: 10.1245/s10434-015-4550-z. Epub 2015 Apr 14.

45. Jonathan Carter. Fast-Track Surgery in Gynaecology and Gynaecologic Oncology: A Review of a Rolling Clinical Audit. ISRN Surgery. Vol. 2012, Article ID 368014, 19 pages, 2012.

46. Nelson G., Bakkum-Gamez J., Kalogera E. et al Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations - 2019 update International Journal of Gynecologic Cancer Published Online First: 15 March 2019. doi: 10.1136/ijgc-2019-000356.

47. De Almeida E.P.M., De Almeida J.P., Landoni G., Galas F.R.B.G., Fukushima J.T., Fominskiy E., De Brito C.M.M., (...), Hajjar L.A. Early mobilization programme improves functional capacity after major abdominal cancer surgery: A randomized controlled trial. (2017) British Journal of Anaesthesia, 119 (5). - Pp. 900 - 907.

48. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward//Journal of the American College of Surgeons. - 2010. - Vol. 210, N 4 - pp. 491 - 495.

49. Peedicayil A., Weaver A., Li X., Carey E., Cliby W., Mariani A. Incidence and timing of venous thromboembolism after surgery for gynecological cancer//Gynecologic Oncology. - 2011. - Vol. 121, N 1. - Pp. 64 - 69.

50. Swarm R., Abernethy A.P., Anghelescu D.L. et al. NCCN Adult Cancer Pain. Adult cancer pain. J Natl Compr Canc Netw. 2010; 8: 1046 - 1086.

51. Ben-Arye E., Samuels N., Lavie O. Integrative Medicine for Female Patients with Gynecologic Cancer//The Journal of Alternative and Complementary Medicine. - Vol. 24, N 9 - 10.

52. Goerling U., Jaeger C., Walz A. et al. The efficacy of psycho-oncological interventions for women with gynaecological cancer: A randomized study//Oncology. 2014; 87: 114 - 124. Crossref, Medline.

53. Smits A., Lopes A., Bekkers R. et al. Body mass index and the quality of life of endometrial cancer survivors - a systematic review and meta-analysis//Gynecol Oncol 2015; 137: 180 - 7. doi:10.1016/j.ygyno.2015.01.540.

54. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42: 1409 - 26.

55. Zhou Y. et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. Gynecol Oncol, 2014. 133 (1): p. 4 - 10.

56. Biglia N., Zanfagnin V., Daniele A., Robba E., Bounous V.E. Lower Body Lymphedema in Patients with Gynecologic Cancer. Anticancer Res. 2017 Aug; 37 (8): 4005 - 4015.

57. Shaitelman S.F., Cromwell K.D., Rasmussen J.C., Stout N.L., Armer J.M., Lasinski B.B., Cormier J.N. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015 Jan - Feb; 65 (1): 55 - 81. doi: 10.3322/caac.21253. Epub 2014 Nov 19. Erratum in: CA Cancer J Clin. 2015 May - Jun; 65 (3): 252. PubMed PMID: 25410402; PubMed Central PMCID: PMC4808814.

58. Borman P. Lymphedema diagnosis, treatment, and follow-up from the view point of physical medicine and rehabilitation specialists. Turk J Phys Med Rehab 2018; 64 (3): 179 - 197.

59. Piller N., Douglass J., Heidenreich B., Moseley A. Placebo controlled trial of mild electrical stimulation. Journal of Lymphoedema. - 2010. - Vol 5, N 1. - P. 15 - 25.

60. Грушина Т.И. Реабилитация в онкологии: физиотерапия. - М.: ГЭОТАР-Медиа, 2006. - 240 с.

61. McNeely M.L., Peddle C.J., Yurick J.L., Dayes I.S., Mackey J.R. Conservative and dietary interventions for cancer-related lymphedema: A Systematic review and meta-analysis. Cancer. 2011 Mar 15; 117 (6): 1136 - 48.

62. Zhang Y.L., Huiling L., Yan L., Li H., Tian B. Effects of acupuncture on cancer-related fatigue: a meta-analysis//Supportive Care in Cancer. - 2018. - V. 26, Issue 2. - Pp. 415 - 425.

63. Carmody J.F., Crawford S., Salmoirago-Blotcher E., Leung K., Churchill L., Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause. 2011 June; 18 (6): 611 - 20. doi: 10.1097/gme.0b013e318204a05c.

64. Ferrandina G., Petrillo M., Mantegna G., Fuoco G., Terzano S., Venditti L., Marcellusi A., De Vincenzo R., Scambia G. Evaluation of quality of life and emotional distress in endometrial cancer patients: a 2-year prospective, longitudinal study. Gynecol Oncol. 2014 Jun; 133 (3): 518 - 25. doi: 10.1016/j.ygyno.2014.03.015.

65. Donoyama N., Satoh T., Hamano T. et al. Physical effects of Anma therapy (Japanese massage) for gynecologic cancer survivors: A randomized controlled trial. Gynecol Oncol 2016; 142: 531 - 538. Crossref, Medline, Google Scholar.

66. Armbruster S.D., Song J., Bradford A. et al. Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis. Gynecol Oncol 2016; 143: 589 - 595. Crossref, Medline, Google Scholar.

67. Huffman L.B., Hartenbach E.M., Carter J., Rash J.K., Kushner D.M. Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. Gynecol Oncol. 2016 Feb; 140 (2): 359 - 68. doi: 10.1016/j.ygyno.2015.11.010. Epub 2015 Nov 7. PubMed PMID: 26556768; PubMed Central PMCID: PMC4835814.

68. Dumoulin C., Cacciari L.P., Hay-Smith E.J.C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews 2018, Issue 10.

69. Hu H., Xie Z.G., Qin W.L. Effect of electroacupuncture intervention at different phases of post-operation on bladder function in patients undergoing cervical cancer operation. Zhen Ci Yan Jiu 2013; 38: 64 - 67, 77. Medline, Google Scholar.

70. Cannioto R.A., Moysich K.B. Epithelial ovarian cancer and recreational physical activity: A review of the epidemiological literature and implications for exercise prescription. Gynecol Oncol, 2015. 137 (3): P. 559 - 73.

71. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol. 2012; 127 (3): 156 - 64. Epub 2012 Jan 31.

72. Mustian K.M., Alfano C.M., Heckler C. et al: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3: 961 - 968.

73. Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H1., Torres M.A., Dunlop B.W., Rakofsky J.J., Rapaport M.H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018 Feb 1; 124 (3): 546 - 554. doi: 10.1002/cncr.31064.

74. Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 1304.

75. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26: 1019 - 1028.

76. Muzi J.L., Look R.M., Turner C., Gardiner S.K., Wagie T., Douglas J., Sorenson L., Evans L., Kirchner S., Dashkoff C., Garrett K., Johnson N. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9019 - 9019.

77. Rick O., von Hehn U., Mikus E., Dertinger H. & Geiger G. (2016). Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics, 38 (2), 85 - 94.

78. M., A., S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014 May; 46 (5): 454 - 60. doi: 10.2340/16501977-1271.

79. Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One. 2014 Sep 8; 9 (9): e107418. doi: 10.1371/journal.pone.0107418. eCollection 2014.

80. Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs. 2017 Apr 1; 21 (2): 226 - 233. doi: 10.1188/17.CJON.226-233.

81. Avci P., Gupta G.K., Clark J., Wikonkal N. & Hamblin M.R. (2013). Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in surgery and medicine, 46 (2), 144 - 51.

82. Spence Rosalind R. et al. Exercise and cancer rehabilitation: A systematic review. Cancer Treatment Reviews. - V. 36, Issue 2. - P. 185 - 194.

83. T.R., Freitas-Junior R., Freitas N.M., Machado G.D. Fatigue related to radiotherapy for breast and/or gynaecological cancer: a systematic review. Fatigue related to radiotherapy for breast and/or gynaecological cancer: a systematic review.

84. Lin K.Y., Edbrooke L., Granger C.L., Denehy L., Frawley H.C. The impact of gynaecological cancer treatment on physical activity levels: a systematic review of observational studies. Braz J Phys Ther. 2019 Mar - Apr; 23 (2): 79 - 92.

85. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg. 2015; 33 (10): 487 - 491.

86. Zhou Q. et al. Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer//Climacteric. - 2018. - T. 21. - N. 1. - С. 60 - 68.

87. Nomelini R.S. et al. Parameters of blood count and tumor markers: a retrospective analysis and relation to prognostic factors in ovarian cancer//Eur J Gynaecol Oncol. - 2017. - T. 38. - С. 364 - 67.

88. Ma X. et al. Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer//Journal of Obstetrics and Gynaecology Research. - 2014. - T. 40. - N. 1. - С. 178 - 183.

89. Qin Y. et al. The value of red cell distribution width in patients with ovarian cancer//Medicine. - 2017. - T. 96. - N. 17.

90. Slabuszewska-Jozwiak A. et al. The prognostic significance of thrombocytosis in ovarian cancer//Annals of Agricultural and Environmental Medicine. - 2015. - T. 22. - N. 4.

91. Yang Z. et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies//Oncotarget. - 2017. - T. 8. - N. 28. - С. 46414.

92. Schneider D. et al. Peritoneal fluid lactate dehydrogenase in ovarian cancer//Gynecologic oncology. - 1997. - T. 66. - N. 3. - С. 399 - 404.

93. Gu P. et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis//European journal of radiology. - 2009. - T. 71. - N. 1. - С. 164 - 174.

94. Ferraro S. et al. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review//Journal of clinical pathology. - 2013. - T. 66. - N. 4. - С. 273 - 281.

95. Zhong Q. et al. Effects of BRCA1-and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis//Clinical Cancer Research. - 2015. - T. 21. - N. 1. - С. 211 - 220.

96. Roze J.F. et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer//Cochrane Database of Systematic Reviews. - 2018. - N. 10.

97. Nam E.J. et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI//Gynecologic oncology. - 2010. - T. 116. - N. 3. - С. 389 - 394.

98. Fischerova D. et al. Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study//Ultrasound in Obstetrics & Gynecology. - 2017. - T. 49. - N. 2. - С. 263 - 274.

99. P.C., K.J. Screening for breast cancer with mammography//Cochrane database of systematic reviews. - 2013. - N. 6.

100. Wubulihasimu, M., Maimaitusun, M., Xu, X.-L., Liu, X.-D., & Luo, B.-M. (2018). The added value of contrast-enhanced ultrasound to conventional ultrasound in differentiating benign and malignant solid breast lesions: a systematic review and meta-analysis. Clinical Radiology. doi:10.1016/j.crad.2018.06.004

101. Hu, Q., Wang, X.Y., Zhu, S.Y., Kang, L.K., Xiao, Y.J., & Zheng, H.Y. (2015). Meta-analysis of contrast-enhanced ultrasound for the differentiation of benign and malignant breast lesions. Acta Radiologica, 56 (1), 25 - 33. doi:10.1177/0284185113517115

102. Elattar A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer//Cochrane database of systematic reviews. - 2011. - N. 8. 2A

103. Huo Y.R. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis//European Journal of Surgical Oncology (EJSO). - 2015. - T. 41. - N. 12. - С. 1578 - 1589.

104. Cardenas-Goicoechea J. et al. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis//Journal of robotic surgery. - 2019. - T. 13. - N. 1. - С. 23 - 33.

105. Elattar A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer//Cochrane database of systematic reviews. - 2011. - N. 8. 2A

106. Huo Y.R. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis//European Journal of Surgical Oncology (EJSO). - 2015. - T. 41. - N. 12. - С. 1578 - 1589.

107. Cardenas-Goicoechea J. et al. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis//Journal of robotic surgery. - 2019. - T. 13. - N. 1. - С. 23 - 33.

108. Elattar A. et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer//Cochrane database of systematic reviews. - 2011. - N. 8. 2A

109. Yang L. et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome//PloS one. - 2017. - T. 12. - N. 10. - С. e0186725.

110. Xiao Y. et al. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis//Gynecologic and obstetric investigation. - 2018. - T. 83. - N. 3. - С. 209 - 219.

111. Zhou J., Shan G., Chen Y. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis//Japanese journal of clinical oncology. - 2016. - T. 46. - N. 8. - С. 718 - 726.

112. Lawrie T.A. et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer//Cochrane Database of Systematic Reviews. - 2015. - N. 12.

113. Lawrie T.A. et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer//Cochrane Database of Systematic Reviews. - 2015. - N. 12.

114. Li, J., Zhou, L., Chen, X., & Ba, Y. (2015). Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. Clinical and Translational Oncology, 17 (9), 673 - 683. doi: 10.1007/s12094-015-1293-z

115. Chen H. et al. Maintenance chemotherapy for ovarian cancer//Cochrane database of systematic reviews. - 2013. - N. 6.

116. Lawrie T.A. et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer//Cochrane Database of Systematic Reviews. - 2015. - N. 12.

117. Al Rawahi T. et al. Surgical cytoreduction for recurrent epithelial ovarian cancer//Cochrane Database of Systematic Reviews. - 2013. - N. 2

118. Wiggans A.J. et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer//Cochrane Database of Systematic Reviews. - 2015. - N. 5.

119. Einhorn, N. (1996). Ovarian Cancer. Acta Oncologica, 35 (sup7), 86 - 92. doi:10.3109/02841869609101668

120. Lawvere, Silvana. (2002). The effect of massage therapy in ovarian cancer patients. 10.1016/B978-0-7234-3217-3.50009-0.

121. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [published online October 21, 2018]. N Engl J Med. doi:10.1056/NEJMoa1810858,

122. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366 (15): 1382 - 1392;

123. Pearl M.L. et al. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients//Cancer nursing. - 1999. - T. 22. - N. 4. - С. 307 - 311.

124. Cui, Ranliang et al. "Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis." Cancer management and research vol. 11 2545 - 2551. 28 Mar. 2019, doi: 10.2147/CMAR.S199400

125. Dochez, V., Caillon, H., Vaucel, E. et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res 12, 28 (2019) doi: 10.1186/s13048-019-0503-7

126. Holme . et al. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials//bmj. - 2017. - T. 356. - С. i6673

127. van de Vrie R, Rutten MJ, Asseler J, Leeflang MMG, Kenter GG, Mol BJ, Buist M. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. N: CD009786. DOI: 10.1002/14651858.CD009786.pub3

128. Makrilia, Nektaria et al. "Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review." Metal-based drugs vol. 2010 (2010): 207084. doi:10.1155/2010/207084

129. Katsumata N et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17; 374 (9698): 1331 - 8. doi: 10.1016/S0140-6736(09) 61157-0. Epub 2009 Sep 18

130. Kurman A., P.J. Hoskins, A.V. Tinker Clinical oncology (Royal College of Radiologists (Great Britain)), ISSN: 1433 - 2981, Vol: 27, Issue: 1, Page: 40 - 7 Publication Year 2015 https://doi.org/10.1016/j.clon.2014.10.001

131. Armstrong D.K. et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer/N Engl J Med 2006; 354: 34 - 43 DOI: 10.1056/NEJMoa052985

132. Kristeleit R et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecol Oncol. 2017 Sep; 146 (3): 484 - 490. doi: 10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.

133. Al Rawahi T. et al. Surgical cytoreduction for recurrent epithelial ovarian cancer//Cochrane Database of Systematic Reviews. - 2013. - N. 2.

134. Lawrie T.A. et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer//Cochrane Database of Systematic Reviews. - 2013. - N. 7.

135. Ray-Coquard, I et al. "Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group." British journal of cancer vol. 100, 4 (2009): 601 - 7. doi:10.1038/sj.bjc.6604878

136. Recchia F. et al. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer/Anticancer Drugs. 2003 Sep; 14 (8): 633 - 8/DOI:10.1097/00001813-200309000-00008

137. Harnett P et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study/Int J Gynecol Cancer. 2007 Mar - Apr; 17 (2): 359 - 66./10.1111/j.1525-1438.2007.00763.x

138. Sugiyama T. et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer./Cancer Lett. 1998 Jun 19; 128 (2): 211 - 8./DOI:10.1016/s0304-3835(98)00065-2

139. Bajetta E et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease./J Clin Oncol. 1996 Sep; 14 (9): 2546-51./DOI:10.1200/JCO.1996.14.9.2546

140. Sehouli J et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group./J Clin Oncol. 2011 Jan 10; 29 (2): 242 - 8. doi: 10.1200/JCO.2009.27.8911. Epub 2010 Nov 29/DOI: 10.1200/JCO.2009.27.8911

141. Poveda, A et al. "Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer." Annals of oncology: official journal of the European Society for Medical Oncology vol. 28, 6 (2017): 1280 - 1287. doi:10.1093/annonc/mdx111

142. Vergote I et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer./ur J Cancer. 2009 May; 45 (8): 1415 - 23. doi: 10.1016/j.ejca.2008.12.013. Epub 2009 Jan 23/DOI:10.1016/j.ejca.2008.12.013

143. El-Husseiny K et al. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. Int J Gynecol Cancer. 2016 Mar; 26 (3): 437 - 42. doi: 10.1097/IGC.0000000000000647

144. Langdon SP et al. Endocrine therapy in epithelial ovarian cancer./Expert Rev Anticancer Ther. 2017 Feb; 17 (2): 109 - 117. doi: 10.1080/14737140.2017.1272414. Epub 2016 Dec 24./DOI:10.1080/14737140.2017.12724

145. Oza A.M. et al. Standart chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7)^ overall survival results of a phase3 randomised trial/V16/(8) P 928 - 936

146. Kew F. et al. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment//Cochrane Database of Systematic Reviews. - 2011. - N. 6.

147. Gershenson D.M. et al. A phase I study of a daily x 3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer//Gynecologic oncology. - 1998. - T. 70. - N. 3. - С. 404 - 409.

148. Wolf J.K. et al. A phase II trial of oral capecitabine in patients with platinum-and taxane-refractory ovarian, fallopian tube, or peritoneal cancer//Gynecologic oncology. - 2006. - T. 102. - N. 3. - С. 468 - 474.

149. Conteduca V, Gurioli G, Rossi L et al. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer; 2018: 1267 (2018).

150. Kumar A. et al. Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer: An Analysis of Outcomes Obtained With Oral Etoposide/Am J Clin Oncol. 2018 Apr; 41 (4): 379 - 384. doi: 10.1097/COC.0000000000000281

151. Gynecologic Oncology Group, Markman M, Blessing J et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jun; 101 (3): 436 - 40.

152. Zhou M. et al. Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer./Journal of Clinical Oncology 2018 36: 15 suppl, 5547 - 5547.

153. AJCC. PART III: digestive systems. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 103 - 26